Details for New Drug Application (NDA): 202236

✉ Email this page to a colleague

NDA 202236 describes DYMISTA, which is a drug marketed by Mylan Speciality Lp and is included in one NDA. It is available from two suppliers. There are two patents protecting this drug and one Paragraph IV challenge. Additional details are available on the DYMISTA profile page.

The generic ingredient in DYMISTA is azelastine hydrochloride; fluticasone propionate. There are twelve drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the azelastine hydrochloride; fluticasone propionate profile page.

Summary for 202236

Tradename:	DYMISTA
Applicant:	Mylan Speciality Lp
Ingredient:	azelastine hydrochloride; fluticasone propionate
Patents:	2

Pharmacology for NDA: 202236

Mechanism of Action	Corticosteroid Hormone Receptor Agonists Histamine H1 Receptor Antagonists

Suppliers and Packaging for NDA: 202236

Tradename	Generic Name	Dosage	NDA	Application Type	Supplier	National Drug Code	Package Code	Package
DYMISTA	azelastine hydrochloride; fluticasone propionate	SPRAY, METERED;NASAL	202236	NDA	Meda Pharmaceuticals Inc.	0037-0245	0037-0245-23	1 BOTTLE, SPRAY in 1 BOX (0037-0245-23) / 120 SPRAY, METERED in 1 BOTTLE, SPRAY
DYMISTA	azelastine hydrochloride; fluticasone propionate	SPRAY, METERED;NASAL	202236	NDA AUTHORIZED GENERIC	Mylan Pharmaceuticals Inc.	0378-3458	0378-3458-23	1 BOTTLE in 1 BOX (0378-3458-23) / 120 SPRAY, METERED in 1 BOTTLE

Profile for product number 001

Active Rx/OTC/Discontinued:	RX	Dosage:	SPRAY, METERED;NASAL			Strength	0.137MG/SPRAY;0.05MG/SPRAY
Approval Date:	May 1, 2012	TE:	AB	RLD:	Yes
Patent:	8,163,723*PED	Patent Expiration:	Feb 29, 2024	Product Flag?		Substance Flag?		Delist Request?
Patent:	8,168,620*PED	Patent Expiration:	Aug 24, 2026	Product Flag?		Substance Flag?		Delist Request?	Y

Expired US Patents for NDA 202236

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Mylan Speciality Lp	DYMISTA	azelastine hydrochloride; fluticasone propionate	SPRAY, METERED;NASAL	202236-001	May 1, 2012	8,163,723*PED	⤷ Subscribe
Mylan Speciality Lp	DYMISTA	azelastine hydrochloride; fluticasone propionate	SPRAY, METERED;NASAL	202236-001	May 1, 2012	9,901,585	⤷ Subscribe
Mylan Speciality Lp	DYMISTA	azelastine hydrochloride; fluticasone propionate	SPRAY, METERED;NASAL	202236-001	May 1, 2012	9,259,428*PED	⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.